Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 6
Submit an article Journal homepage
171
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: results from a seroprevalence study

Simone Claudiania Department of Immunology and Inflammation, Faculty of Medicine, Centre for Haematology, Hammersmith Campus, Imperial College London, London, UKCorrespondence[email protected]
,
Eleanor L. Parkerb Department of Infectious Disease, Faculty of Medicine, St Mary’s Campus, Imperial College London, London, UK
,
Dragana Milojkovica Department of Immunology and Inflammation, Faculty of Medicine, Centre for Haematology, Hammersmith Campus, Imperial College London, London, UK
,
Carolina Rosadasb Department of Infectious Disease, Faculty of Medicine, St Mary’s Campus, Imperial College London, London, UK
,
Afzal Khana Department of Immunology and Inflammation, Faculty of Medicine, Centre for Haematology, Hammersmith Campus, Imperial College London, London, UK
,
Ksenia Katsanovskajab Department of Infectious Disease, Faculty of Medicine, St Mary’s Campus, Imperial College London, London, UK
,
Federica Marchesinb Department of Infectious Disease, Faculty of Medicine, St Mary’s Campus, Imperial College London, London, UK
,
Maryam Khanb Department of Infectious Disease, Faculty of Medicine, St Mary’s Campus, Imperial College London, London, UK
,
Richard S. Tedderb Department of Infectious Disease, Faculty of Medicine, St Mary’s Campus, Imperial College London, London, UK
,
Andrew J. Innesa Department of Immunology and Inflammation, Faculty of Medicine, Centre for Haematology, Hammersmith Campus, Imperial College London, London, UK
,
Myra O. McClureb Department of Infectious Disease, Faculty of Medicine, St Mary’s Campus, Imperial College London, London, UK
&
Jane F. Apperleya Department of Immunology and Inflammation, Faculty of Medicine, Centre for Haematology, Hammersmith Campus, Imperial College London, London, UK
 show all
Pages 1504-1507 | Received 11 Dec 2021, Accepted 04 Jan 2022, Published online: 24 Jan 2022

References

  • Passamonti F, Cattaneo C, Arcaini L, ITA-HEMA-COV Investigators, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737–e745.
  • Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–3173.
  • Ghione P, Gu JJ, Attwood K, et al. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies. Blood. 2021;138(9):811–814.
  • Re D, Barriere J, Chamorey E, et al. Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies. Leuk Lymphoma. 2021;62(13):3308–3310.
  • Breccia M, Abruzzese E, Accurso V, et al. COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A campus CML report. Br J Haematol. 2021 Oct 11 (online ahead of print).
  • Rea DMM, Cortes JE, Jiang Q, et al. COVID-19 in patients (pts) with chronic myeloid leukemia (CML): results from the international CML foundation (iCMLf) CML and COVID-19 (CANDID) study. Blood. 2020;136(Supplement 1):46–47.
  • Harrington P, Doores KJ, Radia D, et al. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. Br J Haematol. 2021;194(6):999–1006.
  • Rosadas C, Randell P, Khan M, et al. Testing for responses to the wrong SARS-CoV-2 antigen? Lancet. 2020;396(10252):e23.
  • Smith G, Apperley J, Milojkovic D, British Society for Haematology, et al. A british society for haematology guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020;191(2):171–193.
  • Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984.
  • Ward H, Atchison C, Whitaker M, et al. SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. Nat Commun. 2021;12(1):905.
  • Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242.
  • Innes AJ, Cook LB, Marks S, et al. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection. Br J Haematol. 2020;190(4):e198–e200.
  • Li C, Yu D, Wu X, et al. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan. Nat Commun. 2021;12(1):4144.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.